Bristol-Myers to buy Celgene in a $74 billion deal

Daniel Acker | Bloomberg | Getty Images

Coumadin medication by Bristol-Myers Squibb on pharmacy shelf in Princeton, Illinois.

Celgene shares surged 32 percent in premarket trading on Thursday after Bristol-Myers Squibb announced plans to buy the biotechnology company in a cash and stock deal valued at $74 billion.

Under the agreement, Celgene shareholders will receive 1 Bristol-Myers Squibb share and $50 in cash for each share of Celgene.

Shares of Bristol-Myers Squibb were down more than 13 percent in early trading.

“Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases,” Bristol-Myers Squibb Chairman and CEI Giovanni Caforio said in a press release.

The boards of directors of both companies approved the deal.

Celgene was set to lose patent protection by 2022 for Revlimid, its top-selling multiple myeloma drug.

The company has been working on an experimental new gene therapy called CAR T-cell therapy — taking a patient’s own immune cells, called T cells, genetically manipulating them to attack specific proteins on cancer, and infusing them back into the patient.

This story is developing. Please check back for updates.

Be the first to comment

Leave a Reply

Your email address will not be published.